Keryx Biopharma (KERX) Misses Q3 EPS by 2c

Keryx Biopharma (NASDAQ: KERX) reported Q3 EPS of ($0.20), $0.02 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $15 million versus the consensus estimate of $18.04 million.

For earnings history and earnings-related data on Keryx Biopharma (KERX) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown